WIRED spoke with DeepMind’s Pushmeet Kohli about the recent past—and promising future—of the Nobel Prize-winning research project that changed biology and chemistry forever. To understand what the ...

eSpeaks’ Corey Noles talks with Rob Israch, President of Tipalti, about what it means to lead with Global-First Finance and how companies can build scalable, compliant operations in an increasingly ...

The Carolina Panthers have more problems than they know what to do with. Offensively, their quarterback is lagging behind in his development. Their offensive line can't protect him. Their run game is ...

TL;DR: Capcom will end support for Monster Hunter games on Windows 10 after the OS reaches its October 14, 2025, End of Life deadline. That means future updates for Monster Hunter titles might break ...

GameSpot may get a commission from retail offers. As it currently stands, playing Monster Hunter Wilds on PC can be a subpar experience. It's had plenty of issues since launch, and while it's better ...

I absolutely love Monster Hunter Wilds, which makes it all the more painful to see it run into so many problems. The latest entry in the Capcom series has been plagued with performance issues on PC ...

The most sober a crack addict ever sounds is when he’s talking about the science of, well, crack. Amid three hours of screaming about George Clooney, the illegal immigrants responsible for cleaning ...

SAVANNAH, Ga. (WSAV) – An Army couple moved out of their home at Hunter Army Airfield (HAA) due to a mold problem, something they said staff could not adequately solve. Hannah Blondo and her husband, ...

Share on Pinterest As the Nimbus variant increases in the U.S., many are reporting an unusually intense sore throat, described as feeling like swallowing razor blades. Ozgur Cankaya/Getty Images The ...

If you buy that artificial intelligence is a once-in-a-species disruption, then what Demis Hassabis thinks should be of vital interest to you. Hassabis leads the AI charge for Google, arguably the ...

Regeneron Pharmaceuticals announced promising results from the Phase 3 C-POST trial of Libtayo (cemiplimab), a PD-1 inhibitor for patients with high-risk cutaneous squamous cell carcinoma (CSCC) ...